LinkedIn Profile

Access Spring Bank Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:sbph 10923306 Dec 3rd, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 570 21.00 Open Biotechnology Dec 2nd, 2020 10:01PM Dec 2nd, 2020 10:01PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Dec 2nd, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 570 21.00 Open Biotechnology Dec 1st, 2020 10:00PM Dec 1st, 2020 10:00PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Dec 1st, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 570 21.00 Open Biotechnology Nov 30th, 2020 10:02PM Nov 30th, 2020 10:02PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 30th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 570 21.00 Open Biotechnology Nov 30th, 2020 10:36AM Nov 30th, 2020 10:36AM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 29th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 569 21.00 Open Biotechnology Nov 28th, 2020 10:01PM Nov 28th, 2020 10:01PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 28th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 569 21.00 Open Biotechnology Nov 27th, 2020 10:01PM Nov 27th, 2020 10:01PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 27th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 569 23.00 Open Biotechnology Nov 26th, 2020 10:01PM Nov 26th, 2020 10:01PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 26th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 569 23.00 Open Biotechnology Nov 26th, 2020 09:51AM Nov 26th, 2020 09:51AM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 25th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 569 23.00 Open Biotechnology Nov 25th, 2020 01:19PM Nov 25th, 2020 01:19PM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals
nasdaq:sbph 10923306 Nov 24th, 2020 12:00AM Spring Bank Pharmaceuticals, Inc. 569 23.00 Open Biotechnology Nov 24th, 2020 09:29AM Nov 24th, 2020 09:29AM We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications. Open Open 86 South Street Hopkinton MA US 01748 Spring Bank Pharmaceuticals

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.